[go: up one dir, main page]

IL142056A0 - Process for obtaining hmg-coa reductase inhibitors of high purity - Google Patents

Process for obtaining hmg-coa reductase inhibitors of high purity

Info

Publication number
IL142056A0
IL142056A0 IL14205699A IL14205699A IL142056A0 IL 142056 A0 IL142056 A0 IL 142056A0 IL 14205699 A IL14205699 A IL 14205699A IL 14205699 A IL14205699 A IL 14205699A IL 142056 A0 IL142056 A0 IL 142056A0
Authority
IL
Israel
Prior art keywords
coa reductase
reductase inhibitors
hmg
purity
chemical synthesis
Prior art date
Application number
IL14205699A
Other languages
English (en)
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Publication of IL142056A0 publication Critical patent/IL142056A0/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01DSEPARATION
    • B01D15/00Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08Selective adsorption, e.g. chromatography
    • B01D15/42Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/422Displacement mode
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00Preparation of carboxylic acid esters
    • C07C67/48Separation; Purification; Stabilisation; Use of additives
    • C07C67/52Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
IL14205699A 1998-09-18 1999-09-17 Process for obtaining hmg-coa reductase inhibitors of high purity IL142056A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9800241A SI20072A (sl) 1998-09-18 1998-09-18 Postopek za pridobivanje inhibitorjev HMG-CoA reduktaze
PCT/IB1999/001553 WO2000017182A1 (en) 1998-09-18 1999-09-17 PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY

Publications (1)

Publication Number Publication Date
IL142056A0 true IL142056A0 (en) 2002-03-10

Family

ID=20432332

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14205699A IL142056A0 (en) 1998-09-18 1999-09-17 Process for obtaining hmg-coa reductase inhibitors of high purity
IL142056A IL142056A (en) 1998-09-18 2001-03-18 Process for obtaining high-purity HMG – CoA reductase inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL142056A IL142056A (en) 1998-09-18 2001-03-18 Process for obtaining high-purity HMG – CoA reductase inhibitors

Country Status (22)

Country Link
US (1) US6695969B1 (xx)
EP (1) EP1114040B1 (xx)
JP (1) JP3795755B2 (xx)
KR (1) KR100607608B1 (xx)
CN (1) CN1186335C (xx)
AT (1) ATE284396T1 (xx)
AU (1) AU766630B2 (xx)
BG (1) BG64676B1 (xx)
CA (1) CA2343645A1 (xx)
DE (1) DE69922519T2 (xx)
HR (1) HRP20010045B1 (xx)
HU (1) HUP0102997A2 (xx)
IL (2) IL142056A0 (xx)
IS (1) IS2149B (xx)
NZ (1) NZ509582A (xx)
PL (1) PL200336B1 (xx)
RO (1) RO121116B1 (xx)
RS (1) RS49996B (xx)
RU (1) RU2235098C2 (xx)
SI (1) SI20072A (xx)
SK (1) SK285868B6 (xx)
WO (1) WO2000017182A1 (xx)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20305A (sl) * 1999-08-06 2001-02-28 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristali natrijeve soli pravastatina
US7141602B2 (en) * 1998-09-18 2006-11-28 Lek Pharmaceuticals D.D. Process for obtaining HMG-CoA reductase inhibitors of high purity
HUP9902352A1 (hu) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Eljárás pravasztatin mikrobiológiai előállítására
EP1265604B1 (en) * 1999-11-30 2006-10-18 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
IL150187A0 (en) * 1999-12-14 2002-12-01 Biogal Pharmaceutical Co Ltd Novel forms of pravastatin sodium
DE01913139T1 (de) * 2000-03-03 2005-03-31 Plus Chemical S.A. Ein verfahren zur reinigung von lovastatin und simvastatin mit verringertem gehalt an dimeren verunreinigungen
US20050215636A1 (en) * 2000-10-05 2005-09-29 Vilmos Keri Pravastatin sodium substantially free of pravastatin lactone and EPI-pravastatin, and compositions containing same
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
US6936731B2 (en) 2000-10-05 2005-08-30 TEVA Gyógyszergyár Részvénytársaság Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (ja) 2000-10-16 2001-12-10 三共株式会社 プラバスタチンを精製する方法
JP3463875B2 (ja) 2001-08-06 2003-11-05 三共株式会社 プラバスタチンを精製する方法
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
JP2003093045A (ja) * 2001-09-26 2003-04-02 Godo Shusei Co Ltd 有用変換微生物
KR100435078B1 (ko) * 2002-02-08 2004-06-09 종근당바이오 주식회사 심바스타틴의 정제방법
JP3463881B2 (ja) 2002-08-06 2003-11-05 三共株式会社 プラバスタチン又はその薬理上許容される塩の単離・精製方法
EP1613760A2 (en) * 2003-04-01 2006-01-11 Ranbaxy Laboratories, Ltd. Fermentation process for the preparation of pravastatin
US6978908B2 (en) * 2003-09-15 2005-12-27 Gerber Products Company Drinking vessel with adjustable handles
TWI319707B (en) * 2003-11-24 2010-01-21 Method of purifying pravastatin
ES2239533B1 (es) * 2004-03-01 2006-12-16 Ercros Industrial, S.A. Procedimiento para la obtencion de compactina.
CN101124230A (zh) * 2004-09-28 2008-02-13 特瓦制药工业有限公司 制备基本无杂质的阿托伐他汀钙形式的方法
CN102043030A (zh) * 2009-10-22 2011-05-04 北京万全阳光医学技术有限公司 一种用高效液相色谱法测定烟酸辛伐他汀缓释片有关物质的方法
CN102621238A (zh) * 2011-02-01 2012-08-01 北京北大维信生物科技有限公司 一种测定HMG-CoA还原酶抑制剂浓度的方法
CN105985244A (zh) * 2015-02-04 2016-10-05 北京北大维信生物科技有限公司 化合物、其分离方法、合成方法及用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
SU1319352A1 (ru) * 1985-01-07 1995-09-10 Ленинградский государственный университет им.А.А.Жданова Способ очистки препарата гистона н4 из ткани тимуса
IT1232311B (it) * 1989-09-04 1992-01-28 Sclavo Spa Metodo di purificazione di composti a struttura peptidica o pseudo peptidica a basso peso molecolare.
US5202029A (en) 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
US5407050A (en) * 1991-03-14 1995-04-18 Kabushiki Kaisha Ace Denken Article control system
US5420024A (en) * 1993-05-11 1995-05-30 Merck & Co., Inc. Process for synthesis of acylated HMG-CoA reductase inhibitors from a lactone diol precursor using Candida cylindracea
US5427686A (en) 1994-04-05 1995-06-27 Sri International Process for separating material from mixture using displacement chromatography
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process

Also Published As

Publication number Publication date
IL142056A (en) 2006-08-01
CA2343645A1 (en) 2000-03-30
RO121116B1 (ro) 2006-12-29
AU766630B2 (en) 2003-10-23
WO2000017182A1 (en) 2000-03-30
KR100607608B1 (ko) 2006-08-02
RU2235098C2 (ru) 2004-08-27
AU5528499A (en) 2000-04-10
YU81800A (sh) 2003-02-28
HUP0102997A2 (hu) 2001-12-28
BG64676B1 (bg) 2005-11-30
HRP20010045A2 (en) 2001-12-31
EP1114040B1 (en) 2004-12-08
CN1318063A (zh) 2001-10-17
RS49996B (sr) 2008-09-29
JP3795755B2 (ja) 2006-07-12
SI20072A (sl) 2000-04-30
DE69922519T2 (de) 2005-12-08
IS2149B (is) 2006-10-13
PL200336B1 (pl) 2008-12-31
DE69922519D1 (de) 2005-01-13
SK20022000A3 (sk) 2001-08-06
SK285868B6 (sk) 2007-10-04
ATE284396T1 (de) 2004-12-15
JP2002526486A (ja) 2002-08-20
CN1186335C (zh) 2005-01-26
NZ509582A (en) 2003-10-31
BG105348A (en) 2001-11-30
PL345883A1 (en) 2002-01-14
EP1114040A1 (en) 2001-07-11
US6695969B1 (en) 2004-02-24
IS5886A (is) 2001-03-12
HRP20010045B1 (en) 2005-08-31
KR20010099584A (ko) 2001-11-09

Similar Documents

Publication Publication Date Title
HRP20010045B1 (en) PROCESS FOR OBTAINING HMG-CoA REDUCTASE INHIBITORS OF HIGH PURITY
IL187261A0 (en) Crystals of the sodium salt of pravastatin
IL142055A0 (en) New salts of hmg-coa reductase inhibitors
IL143759A0 (en) STABLE PHARMACEUTICAL FORMULATION COMPRISING HMG-CoA REDUCTASE INHIBITORS
AU4943400A (en) Stabilized pharmaceutically effective composition and pharmaceutical formulationcomprising the same
AU1510800A (en) Process for the preparation of simvastatin and analogs thereof
HUP0301423A2 (hu) Eljárás lovasztatin izolálására
AU2000250960A1 (en) Stable pharmaceutical product and formulation
YU88602A (sh) Stabilizovane farmaceutski efektivne smeše i farmaceutske formulacije koje ih sadrže
WO2002100323A3 (en) METHYL ANALOGS OF SIMVASTATIN AS NOVEL HMG-CoA REDUCTASE INHIBITORS

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed